This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alcon's (ALC) Robust Product Line, Market Rebound Aid Growth
by Zacks Equity Research
In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon (ALC) currently leads the market with over 55% of global share and over 80% share in the United States.
Hologic (HOLX) Adds New Products to Omni Hysteroscopy Offering
by Zacks Equity Research
Hologic (HOLX) expands Omni suite in EMEA with the new Omni 30 degree hysteroscope, Omni Lok cervical seal and Omni 5 French seal products.
Illumina (ILMN) Oncology Growth Aids Amid GRAIL Merger Hurdle
by Zacks Equity Research
Illumina (ILMN) is making progress outside the United States to ensure all expecting families have access to NIPT.
Thermo Fisher (TMO) Launches Kit for Safer Sample Collection
by Zacks Equity Research
Thermo Fisher (TMO) launches SpeciMAX Stabilized Saliva Collection Kit that can support global efforts toward SARS-CoV-2 research by ensuring safer saliva collection.
Globus Medical (GMED) Progresses With ExcelsiusGPS in DBS
by Zacks Equity Research
According to Globus Medica (GMED), the clinical superiority of ExcelsiusGPS continues to be recognized by surgeons.
Orthofix (OFIX) Reaches Milestone for M6-C Disc Implants
by Zacks Equity Research
Orthofix (OFIX) reveals that more than 60,000 M6-C artificial cervical discs have been implanted worldwide.
NEOGEN (NEOG) Igenity Branded Calves Score Highest US Sales
by Zacks Equity Research
NEOGEN's (NEOG) Igenity-tested calves earn an average premium of over $59 in the summer selling season.
Thermo Fisher's (TMO) Delta Q IRMS to Back Sustainable Science
by Zacks Equity Research
Thermo Fisher (TMO) has introduced the new Delta Q IRMS under the IsoFootprint campaign to support sustainable science by eliminating carbon dioxide emission.
Here's Why You Should Add Alcon Stock (ALC) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) backed by robust second-quarter performance and raised 2021 outlook.
The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma
4 Stocks to Keep a Watch on Amid Growing Optical Care Demand
by Riya Anand
Stocks like Alcon (ALC), National Vision (EYE), The Cooper Companies (COO) and EyePoint Pharmaceuticals (EYPT) are gaining momentum amid rising optical care demand.
Alcon (ALC) Q2 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Alcon (ALC) records the highest sales in the second quarter of 2021 since its spin-off.
Alcon (ALC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in the Surgical segment and new launches under Vision Care segment are likely to have driven growth in the second quarter for Alcon (ALC).
3 Medical Instruments Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on base business recovery. ISRG, IDXX and ALC are set to gain the most. However, falling demand for COVID-19 tests might disrupt the trend.
Co-Diagnostics (CODX) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Co-Diagnostics' (CODX) second-quarter results are likely to reflect higher COVID-19 test sales.
New Strong Sell Stocks for June 2nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Should You Pick Up Novartis (NVS) Before Q2 Earnings?
by Mitchell Moore
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.